NURS 6630 Week 9 substance use case example

Full Agonist, Partial Agonist or Antagonist at the Mu Receptor: A Case Analysis of Opioid Use Disorder With a Depressive Episode That Came First

Student Name

College of Nursing, Walden University

NURS 6630: Neurobiology and Psychopharmacology for Psychiatric Mental Health Advanced Practice Nursing

Instructor Name

Month Day, Year

Full Agonist, Partial Agonist or Antagonist at the Mu Receptor: A Case Analysis of Opioid Use Disorder With a Depressive Episode That Came First

The Case

An invented thirty-two-year-old warehouse supervisor has opioid use disorder. He began using prescription opioids after a back injury four years ago and has used illicitly obtained opioids daily for the past eighteen months. He wants treatment. His first depressive episode began at twenty-six, before the injury, and his current episode began before his use escalated; he has taken a selective serotonin reuptake inhibitor for a year with partial benefit. He drinks rarely and does not use sedatives. The case asks for a choice among medications for opioid use disorder, reasoned from their action at the mu-opioid receptor, and for a plan that addresses both conditions. Dosing and induction procedures are not described here; which follow established clinical protocols.

Three Strategies at the Mu-Opioid Receptor

A full agonist activates the mu receptor fully, as the opioids he has been using do. As a treatment, a long-acting full agonist replaces short-acting use with steady receptor occupancy, reducing withdrawal and craving. Because activation increases with dose, respiratory depression also increases with dose, and treatment is typically delivered through specialized programs.

A partial agonist binds the mu receptor with very high affinity but activates it only partly. Two consequences follow directly from that binding. First, its effect on breathing reaches a ceiling, which makes respiratory depression less likely when it is taken alone, although the protection is reduced when sedatives or alcohol are added. Second, because it binds more tightly than most other opioids, it can displace them from the receptor. If it is given while a full agonist is still bound, the patient experiences a sudden drop in receptor activation, precipitated withdrawal, which is why treatment begins only when some withdrawal is already present (Substance Abuse and Mental Health Services Administration [SAMHSA], 2021).

An antagonist binds the receptor without activating it and blocks other opioids. It produces no dependence, but it can only begin after a period without opioids, since starting it while opioids are present would cause severe withdrawal, and it offers no relief from craving through receptor activation.

The Choice

The partial agonist is chosen. He wants treatment now and cannot remain opioid-free long enough to begin an antagonist safely, which would also leave him at high overdose risk if he relapsed after losing tolerance. The partial agonist's ceiling on respiratory depression suits a patient who uses no sedatives, and it can be prescribed in office-based settings, which fits his work schedule. Medications for opioid use disorder reduce illicit use and overdose deaths, and expanding access to them has been a national public health priority (Volkow et al., 2014). The predicted risk, precipitated withdrawal at the start, is explained to him in advance, and the start follows the clinic's protocol.

The Depression, Treated as Its Own Condition

Because his depressive episodes began before his opioid use and before its escalation, the case treats the depression as an independent disorder rather than as a consequence of use that will resolve with abstinence. That timeline matters: independent depression is less likely to lift on its own once use stops. His serotonergic antidepressant continues. The combination raises two points. There is no significant receptor-level conflict between his antidepressant and a partial mu agonist, but some other opioids used in treatment or for pain have serotonergic activity, which is worth recording for any future prescriber. And since depression and hopelessness raise overdose risk, suicide risk is assessed at each visit, and he and his family are offered naloxone and taught its use (SAMHSA, 2021).

Monitoring

At each visit: craving and withdrawal symptoms, any opioid use by report and urine testing, sedative or alcohol use, mood using the PHQ-9 and suicide risk. The plan also records his work schedule, since missed appointments are a known reason people leave treatment, and arranges visits outside his shift hours. Counseling is offered and encouraged but is not made a condition for receiving medication, since losing access to medication would expose him to greater overdose risk than declining counseling does. The antidepressant response is reviewed at eight weeks, when the effect of stabilized opioid use on his mood can also be judged (Stahl, 2021).

References

Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.

Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder (Treatment Improvement Protocol TIP 63).

Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies: Tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22), 2063-2066. https://doi.org/10.1056/NEJMp1402780